Introduction

THE THYROTROPIN
(TSH) receptor is expressed on the cell surface membrane of the thyrocyte and plays a critical role in thyroid function and growth [1, 2] . Autoantibodies against the TSH receptor (TSHR) are thought to be involved in the expression of autoimmune thyroid diseases, Graves' disease and some patients with primary myxedema [3] . Thus, studies on the TSHR are important not only to understand hormone actions but also the pathogenesis of autoimmune thyroid diseases. Interesting features of anti-TSHR antibodies (TSHRAb) are their functional heterogeneity.
Autoantibodies which can mimic TSH actions and stimulate thyroid cells are called "thyroid stimulating antibodies (TSAb)", while those which may block TSH actions are called "thyroid-stimulation blocking antibodies (TSBAb)". Antibodies may inhibit TSH binding to the receptor and are called "TSH binding inhibitor immunoglobulins (TBII)" .
To clarify the structure, function and interaction of the TSHR and TSHRAb at the molecular level, we attempted to isolate their genes, respectively. After success of the cloning of the TSHR gene [4] , we further analyzed various structural and functional aspects of the receptor: processing [5] , This review was written as a memorial article for the Shichijo Prize of the Japan Endocrine Society awarded to the authors on October, 20, 1994. Correspondence to: Dr. Takashi AKAMIZU, Department of Laboratory Medicine, Kyoto University School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606, Japan glycosylation [5] [6] [7] , regulation [4, [8] [9] [10] [11] , ligand and antibody binding sites [3, 6, [12] [13] [14] [15] [16] [17] [18] [19] , T cell epitopes [20] , and signal transduction [21, 22] . Regarding with the TSHRAb gene, we isolated TBII and TSAb genes, and analyzed their primary structure [23] . In this review we describe our recent studies regarding cloning and subsequent studies of both genes, TSHR and TSHRAb genes.
TSH Receptor
Cloning of TSHR gene
We tried three procedures for selecting the TSHR gene from recombinant thyroid cell cDNA libraries: 1) immunoscreening with TSHRAb; 2) screening with a synthetic oligonucleotide which is designed based on a portion of the amino acid sequence of purified TSH receptor protein; and 3) screening with cDNAs of receptors belonging to the G-protein coupled or glycoprotein hormone receptor family, such as a-adrenergic receptor and lutropin/chorionic gonadotropin receptor (LH/ CGR). The first approach resulted in the cloning of Ku antigen [24] . The second one failed due to the difficulties of purification of the protein and, in fact, -actin and heat shock protein 70 were eluted from TSH-sepharose [25] . The successful cloning was achieved by the third approach.
The rat TSHR cDNA clone was obtained from screening of a FRTL-5 rat thyroid 2 gt11 expression library using rat LH/CGR cDNA [4] . A 2.8 kb full length clone that encodes a protein of 764 amino acids was obtained as shown in Fig. 1 Nuclear run-on assay suggested that TSH downregulated TSHR transcriptionally. The degree of downregulation in Northern blots agreed with that in nuclear run-on assay [7] . Further studies on the 5'-flanking promotor region of the TSHR gene revealed the transcriptional regulation of the receptor by TSH [10] .
In contrast to TSH, 5% serum, insulin and IGF-1 increase TSH receptor mRNA levels. Hydrocortisone has no effect on receptor mRNA levels. The action of insulin/IGF-1 also reflects transcriptional regulation as evidenced by nuclear run-on assays. Insulin and serum are required for TSH to downregulate the TSHR mRNA levels. Thus, TSH does not downregulate the receptor mRNA levels in the cells maintained in basal medium without insulin or serum.
In contrast, TSH does downregulate its receptor mRNA if the cells are kept in medium with serum, insulin, or the two together.
Processing and glycosylation of TSH receptor
As shown in Fig. 1 , there is a hydrophobic area on the N-terminus of the receptor, presumed to be a putative signal peptide. To confirm this, we used a variant cDNA missing the putative signal peptide, residue 5-23, but otherwise able to encode the full length receptor protein [5] . In in vitro transcription/translation analysis, the full length cDNA gave the most prominent 74 kDa band. In the presence of canine pancreatic microsomal membranes (CMM), full length mRNA yielded a larger sized product, 88 kDa band, suggesting an increase of protein size by glycosylation. In contrast, the mutant RNA gave only 74 kDa band either in the absence or presence of CMM. Endo H dose-dependently digested the 88 kDa band to 74 kDa, confirming that CMM induced TSH receptor processing and glycosylation. These findings show that the initial hydrophobic segment of TSH receptor is a signal peptide and that the signal peptide is necessary for TSH receptor processing and glycosylation.
Mutants missing individual glycosylation sites were created; asparagine was mutated to glutamine in each of 5 glycosylation sites [6, 7] . These mutants were subjected to in vitro transcription/ 2) synthetic peptide and anti-peptide antibody studies, in which specific receptor amino acid sequences deduced from nucleotide sequences are utilized; and 3) epitope library method, in which the linear receptor peptide fragments are expressed in bacteria using a recombinant DNA technique.
Since both peptide and epitope library approaches identify only a linear and non-glycosylated binding sites, we at first started the mutagenesis study using various deletion or substitution mutants.
In the present report, we refer to only the mutagenesis study. We have previously reviewed the peptide studies [3] .
3-i) Deletion mutants
Since an extracellular domain is supposed to be a ligand-or antibody-binding site, several deletion mutants of the extracellular domain of the rat TSH receptor cDNA were created [6] . [12] . At first, these chimeric cDNAs were transfected to Cos-7 cells and subjected to Western blot analysis using anti-receptor peptide antibodies, which were raised against amino acid residues 352-366 of the TSHR.
In Western blot analysis, specific 95 kDa, 180 kDa, and high molecular bands were identified in wild type TSHR and C1 to C6 chimeras, but not in LHR and C7 chimera which does not contain the region recognized by anti-peptide antibody. The results of Western blot showed that most of chimeras were properly synthesized. However, when TSHR activities of these chimeras were measured, none but C5 showed receptor activities. C5 showed that this region is important for TSH binding , but not for signal transdution.
Further studies of C5 revealed that cysteine-301 is a critical residue for this activity [13, 14] . Loss of receptor activities in most chimeras suggested that the substitutions might be too large to prevent them from destroying 3-D structure of the receptor. We therefore next tried smaller deletions or substitutions.
3-iii) Mutagenesis of a portion nonhomologous with gonadotropin receptors
There are two nonhomologous areas between TSHR and LH/CG when amino acids of their extracellular domains were aligned: in the N-terminus and C-terminus. Therefore, we analyzed these two regions in detail.
At first, we analyzed the C-terminus: the C-terminal region was divided into several small segments consisting about 10 amino acids, and deletion or substitution mutants of each segment were constructed [15] . Deletion In summary, our current model is shown in Fig.  2 of antigen-presenting cells (APC). Therefore, synthetic peptides corresponding to the TSHR, the primary sequence of which is known, can be used to define the epitopes recognized by TSHR-specific T cells. Nevertheless, only limited data concerning T cell recognition of TSHR have been reported [3, [28] [29] [30] [31] . Although these previous reports have suggested the existence of multiple T cell epitopes on the receptor, definite epitopes have yet to be determined, and molecular studies of the T cell receptor gene have not yet been performed, either.
Recently, we established a T cell line using a pool of 49 synthetic peptides corresponding to the entire human thyrotropin receptor (TSHR) sequence from the peripheral lymphocytes of a patient with Graves' disease [20] . This T cell line showed a specific response to the pool of peptides in a microproliferation assay (stimulation index: 4.8). Flow cytometry analysis revealed that the cell surface markers were CD4+CD8 T cell receptor (TcR) a j3+ and TcRys-. To investigate T cell epitopes on TSHR, the 49 synthetic peptides were divided into 6 groups, and the responses of the T cell line to each group were tested. The T cell line reacted well against three groups: the N-terminal (amino acids 31-169) and C-terminal (338-420) regions of the extracellular domain and the N-terminal half (441-661) of the transmembrane domain of the receptor. This suggests a multiplicity of T cell epitopes on the TSHR, and was further supported by analysis of TcR gene expression in the cell line which showed the expression of 5 Va genes: Va-1, 2, 10, 20 and w25. These findings indicated multiple T cell epitopes on the TSHR molecule including the transmembrane domain.
In summary, we established a TSHR-specific T cell line and analyzed its usage of TcRa genes. This approach may be an important step to define T cell epitopes on TSHR and to identify TcR genes expressed in TSHR-specific T cell clones. Ultimately, this methodology is expected to lead to further understanding of the pathogenesis of Graves' disease and to new developments in immunotherapy. 
Preparation of monoclonal TSHRAb
As illustrated in Fig 3, lymphocytes from Graves' patients were transformed by EBV and the cultured supernatants were screened for TBII, TSAb and TSBAb. The positive lymphocytes were cloned and their monoclonalities confirmed by Southern blot analyses.
In the first screening studies using Graves' lymphocytes, some cells showed only TBII activities, some showed only TSAb activities and some showed both. However, in the second screening after cloning, surprisingly, all clones producing IgM class antibodies showed either TBII or TSAb activities, never both [23, 36] . This supports the view that TBII and TSAb are different immunoglobulins. This was the case in IgG class TSAbs [37] .
In contrast, in studies using lymphocytes of hy- TSHRAb  GENES   623 pothyroid patients all 20 TBII positive clones obtained were positive in TSBAb activities [38] . Only two TSBAb positive clones had negative TBII activities.
Although there was no significant relationship between TBII and TSBAb activity, most TBII and TSBAb appear to overlap each other. In sum, these findings suggest that TBII in Graves' patients is different from TSAb but that in myxedema patients closely overlaps with TSBAb. Thus the relationships between TBII and TSAb or TSBAb are elucidated.
Ig genes of TSHRAb
Genes encoding the heavy chain are located on the chromosome 14, and those of two light chains, K and X, are on the chromosome 2 and 22, respectively. Each set has a similar organization. The heavy chain locus is composed of multiple genes: variable (V), diversity (D), joining (J) and constant (C) regions. The light chain loci consist of V. J and C. Variable regions of heavy chain are formed by V, D, and J, and those of light chain are by V and J. The diversity of antibodies is generated by the rearrangement of one of these elements. Further diversity may be generated by somatic mutation of rearranged genes. The number of functional VH genes are supposed to be approximately 50 [45, 46] , and more than 20 DH genes and 6 JH genes exist. VH genes are classified into 7 groups based upon their nucleic acid sequence homologies and most genes have been already cloned.
We aimed to clarify the following by analyzing (Fig. 3 ). After isolation of VH genes, they were subcloned into plasmids for sequencing.
Restricted VH gene usage in TSHRAb
Comparing nucleotide sequences of the VH genes in the TBII and TSAb clones with known germline VH segments allowed us to identify the germ-line VH segments used for the TBII and TSAb ( Table 1 ). The strongest evidence for such identification relies on the fact that intron and flanking sequences of the VH genes in the TBII and TSAb clones are completely or almost identical to those of the most homologous germ-line VH segments, although there are many mutations or insertions in coding sequences.
In fact, none of two VH segments among the 64 germ-line segments so far characterized has an identical intron sequence [45] . Thus, genomic VH analysis is advantageous over cDNA analysis for searching for germ-line VH counterparts.
One-or 2-bp discordance between the introns of clones and those of their germ-line counterpart is most likely explained by polymorphism. Interestingly, all TBII genes belonged to VH_III, while TSAb genes were diverse, including VH-II , -III, -IVY and _v. Interestingly, V3-23 were used in two TBII clones and in one TSAb clone.
The most homologous germ-line VH segments of these antibodies have been reported to be used frequently in autoantibodies or in the fetal repertoire except for V2-26 (Table 2 ). V3-53 and V3-7, which are found as germ-line VH counterparts of 280-3 and 296-4, respectively, were reported to be expressed in fetal liver. The germ-line counterpart VH segment (V3-23) of 291-11, 267-9 and 79-4 was also used in 18/2, an anti-DNA antibody, and 30P1 cDNA is found in fetal liver. Similarly, the germline VH segment of 82B is V4-59 which is also 99.4% homologous to 58P2 frequently expressed during the early stage of ontogeny and is 98.6% identical to Pag-1, an autoantibody for D-Ag of the Rh blood group system. V5-51, the germ-line VH segment of 141-1, has been found in antibodies expressed in organ-specific autoimmune diseases, such as myasthenia gravis and insulin-dependent diabetes mellitus.
The fact that common germ-line VH segments are used in TSHRAb, in other autoantibodies and in the fetal liver repertoire suggests that restricted VH segments may be selected for autoantibodies by unknown mechanisms and that there might be a common mechanism for selection of autoantibodies and fetal VH repertoire.
Somatic mutations in TSAb and TBII
Subsequently, somatic mutations of these clones were studied. As a whole, mutation frequencies of the TBII clones are higher than those of the TSAb clones (Table 1) . Moreover, although a number of replacement (R) and silent (S) mutations are found in both CDR and framework region, the R/S ratios of the CDR are considerably higher than those of the framework region, especially in the TBII clones (296-1, 280-3 and 267-9 ). This pattern of somatic mutations in the VH region can only be explained by positive selection on the basis of the ligandreceptor interaction, presumably because these mutated antibodies acquired higher affinities to the TSHR. If R mutations increase affinity of an antibody for the TSHR, the mutations confer a stronger selective advantage to TBII than TSAb because TBII has to compete with TSH for binding to restricted regions of the TSHR. Of course, we have to reserve the possibility that some of the amino acid changes are due to the difference between alleles. Although V3-23 was used for both TBII (291-11 and 267-9) and TSAb (79-4), the positions and frequencies of somatic mutations are different among the three clones. In addition, the number of R mutations in CDR of 291-11 and 267-9 is twice as great as that of 79-4. These results clearly indicate that the same germ-line VH can be used for either TBII and TSAb by different somatic mutations.
D and JH gene utilization
The D segments used in the TSHRAb are heterogeneous in length and sequence, and can only partly be related to previously reported germ-line elements. Junctional diversity which arises from variation in joining sites between different gene segments and the addition of flanking nucleotides (N-insertions) is naturally observed. JH gene utili- 
